Eli Lilly Bets Big on Neuroscience for Its Next Growth Chapter

Fueled by GLP-1 profits, Eli Lilly acquires Centessa for up to $7.8B and expands AI drug discovery to build a new neuroscience growth pillar.

Fueled by unprecedented profits from its blockbuster GLP-1 drugs, Eli Lilly is strategically deploying capital to establish a major new growth pillar. The pharmaceutical giant is making a multi-billion dollar wager on neuroscience, underscored by a planned acquisition and a significant expansion of an artificial intelligence partnership.

Financial Firepower from GLP-1 Success

The company’s aggressive investment strategy is backed by formidable financial strength. In 2025, Eli Lilly reported revenue of $65.2 billion, a 45% year-over-year surge driven primarily by its GLP-1 medications Mounjaro and Zepbound. This performance generated a free cash flow exceeding $15 billion. Management has set an ambitious revenue target of $80 to $83 billion for 2026.

A Multi-Billion Dollar Entry into Sleep Disorders

The centerpiece of this strategic pivot is the acquisition of Centessa Pharmaceuticals. The deal has a total potential value of up to $7.8 billion. Eli Lilly will make an upfront cash payment of approximately $6.3 billion, or $38 per share, representing a 40.5% premium to Centessa’s weighted 30-day average stock price. Contingent value rights of up to $9 per share are also included, tied to achieving specific FDA regulatory milestones by 2030.

The primary asset is the investigational drug cleminorexton, an OX2R agonist currently in Phase 2a studies. Early data indicates it improved wakefulness by 20 minutes in tests involving patients with type-1 narcolepsy. Eli Lilly is targeting a sleep disorder therapy market estimated to be worth $15 to $20 billion, where it will eventually compete with products from Takeda and Alkermes. Takeda’s rival compound, oveporexton, anticipates an FDA decision in 2026, while cleminorexton is not expected to reach the market before 2028.

Leveraging AI to Accelerate Drug Discovery

In a parallel move, Eli Lilly has significantly expanded its collaboration with AI-driven biotech firm Insilico Medicine. For an upfront payment of $115 million, Lilly secured exclusive licenses to several preclinical drug candidates. The total potential value of this agreement could reach $2.75 billion. The broadened partnership now encompasses 28 AI-generated candidates targeting diseases with high unmet medical need.

Market Reception and Analyst Perspective

The strategic announcements were well-received on Wall Street, with Eli Lilly shares advancing approximately 3.1% on the day of the news. Analysts have viewed the moves positively as a long-term value driver. BMO Capital Markets reaffirmed its "Outperform" rating and a $1,300 price target, stating that using GLP-1 proceeds to build a neuroscience segment helps justify the company’s current valuation premium.

Trading around €796, the stock remains about 17% below its 52-week high. For investors, the successful development of a second major growth engine alongside the GLP-1 franchise is poised to become a crucial medium-term valuation factor—contingent on cleminorexton successfully navigating the remaining clinical trial phases ahead of its projected 2028 launch.